Feature Story

A new therapy for treating Type 1 diabetes

October 20, 2021

Promising early results show that longstanding Harvard Stem Cell Institute (HSCI) research may have paved the way for a breakthrough treatment of Type 1 diabetes. Utilizing research from the Melton Lab, Vertex Pharmaceuticals has developed VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes (T1D). In conjunction with immunosuppressive therapy, VX-880 produced robust restoration of islet cell function on Day 90 in the first patient in its Phase 1/2 clinical trial.... Read more about A new therapy for treating Type 1 diabetes

A global conference on the latest stem cell research

July 29, 2020

In June, the Harvard Stem Cell Institute (HSCI) co-sponsored the annual meeting of the International Society for Stem Cell Research. Held virtually for the first time, the conference brought together close to 4,000 scientists from 59 countries to discuss the latest in stem cell research.

David Scadden, co-director of HSCI, opened the conference by welcoming attendees and encouraging researchers to apply their expertise in stem cell science to the ongoing COVID-19 pandemic: “This has been a time of great crisis and upheaval that has really reminded us of the extraordinary power...

Read more about A global conference on the latest stem cell research

Highlights from the 2019 HSCI Annual Retreat

May 30, 2019

Boston-area stem cell scientists convene to discuss regulation, future research directions, career paths

The Harvard Stem Cell Institute (HSCI) convened for its 14th annual retreat on May 21st at Harvard Medical School in the Joseph B. Martin Conference Center. The event was a mix of presentations and panels, with poster sessions and topic tables in the New Research Building’s sunny atrium and courtyard.

Program Highlights

Around 300 HSCI scientists welcomed keynote speaker...

Read more about Highlights from the 2019 HSCI Annual Retreat